Arie S. Belldegrun's most recent trade in Allogene Therapeutics Inc was a trade of 929,913 Stock Option (Right to buy) done . Disclosure was reported to the exchange on Feb. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 929,913 | 929,913 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 263,033 | 263,033 | - | - | Restricted Stock Unit | |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Aug 2025 | 20,000 | 20,000 | - | - | Stock Option (right ot buy) | |
| Kronos Bio Inc | Arie S. Belldegrun | Director | 20 Jun 2025 | 2,765,314 | 0 | - | 0.6 | 1,576,229 | Common Stock | |
| Kronos Bio Inc | Arie S. Belldegrun | Director | 20 Jun 2025 | 679,575 | 0 | - | 0.6 | 387,358 | Common Stock | |
| Kronos Bio Inc | Arie S. Belldegrun | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Jun 2025 | 34,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kronos Bio Inc | Arie S. Belldegrun | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Jun 2025 | 34,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kronos Bio Inc | Arie S. Belldegrun | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Jun 2025 | 34,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kronos Bio Inc | Arie S. Belldegrun | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Jun 2025 | 20,600 | 0 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 1,307,927 | 1,307,927 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 369,957 | 2,236,816 (1%) | 0% | 0 | Common Stock | |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2024 | 10,000 | 10,000 | - | - | Stock Option (right ot buy) | |
| Kronos Bio Inc | Arie S. Belldegrun | Director | 25 Jun 2024 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | ||
| Ginkgo Bioworks Holdings Inc (Class A) | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 571,428 | 571,428 | - | - | Stock Option | |
| Ginkgo Bioworks Holdings Inc (Class A) | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 432,900 | 432,900 | - | - | Restricted Stock Units | |
| Ginkgo Bioworks Holdings Inc (Class A) | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 105,263 | 194,925 | - | - | Class A Common Stock | |
| Ginkgo Bioworks Holdings Inc (Class A) | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 105,263 | 0 | - | - | Restricted Stock Units | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Purchase of securities on an exchange or from another person at price $ 2.90 per share. | 16 May 2024 | 1,724,137 | 1,724,137 (1%) | 1% | 2.9 | 4,999,997 | Common Stock |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 2.90 per share. | 16 May 2024 | 344,828 | 539,867 (0%) | 0% | 2.9 | 1,000,001 | Common Stock |
| Allogene Therapeutics Inc | Belldegrun S. Arie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 749,398 | 749,398 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | Belldegrun Arie S. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 211,973 | 1,866,859 (1%) | 0% | 0 | Common Stock | |
| Kronos Bio Inc | Arie S. Belldegrun | Director | 22 Jun 2023 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | ||
| Ginkgo Bioworks Holdings Inc (Class A) | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 139,860 | 139,860 | - | - | Stock Option | |
| Ginkgo Bioworks Holdings Inc (Class A) | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 105,263 | 105,263 | - | - | Restricted Stock Units | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 1,282,976 | 1,654,886 (1%) | 1% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 994,800 | 994,800 | - | - | Stock Option (Right to Buy) | |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 14 Sep 2022 | 160,000 | 408,693 (1%) | 0% | 5 | 800,000 | Ordinary Shares |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2022 | 160,000 | 0 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2022 | 3,241 | 0 | - | - | Stock Option (right to buy) | |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 31 Aug 2022 | 3,241 | 248,693 (1%) | 0% | 5 | 16,205 | Ordinary Shares |
| Kronos Bio Inc | Arie S. Belldegrun | Director | 22 Jun 2022 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | ||
| Ginkgo Bioworks Holdings Inc (Class A) | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 108,516 | 108,516 | - | - | Stock Option | |
| Ginkgo Bioworks Holdings Inc (Class A) | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 70,921 | 89,662 | - | 0 | Class A Common Stock | |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 1,458,333 | 1,458,333 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Other type of transaction at price $ 0.00 per share. | 14 Mar 2022 | 4,710,120 | 4,710,120 (3%) | 3% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Other type of transaction at price $ 0.00 per share. | 14 Mar 2022 | 4,710,120 | 0 (0%) | 3% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Purchase of securities on an exchange or from another person at price $ 12.60 per share. | 12 Jan 2022 | 155,039 | 195,039 (0%) | 0% | 12.6 | 1,953,491 | Common Stock |
| Kronos Bio Inc | Arie S. Belldegrun | Director | 22 Jun 2021 | 20,600 | 20,600 | - | - | Stock Option (Right to Buy) | ||
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.22 per share. | 24 May 2021 | 379,066 | 583,034 (0%) | 0% | 18.2 | 6,906,583 | Common Stock |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2021 | 379,066 | 0 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2021 | 199,223 | 199,223 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2021 | 53,635 | 203,968 (0%) | 0% | 0 | Common Stock | |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 26 Mar 2021 | 3,241 | 245,452 (1%) | 0% | 5 | 16,205 | Ordinary Shares |
| UroGen Pharma Ltd | Arie S. Belldegrun | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2021 | 3,241 | 0 | - | - | Stock Option (right to buy) |